| Literature DB >> 26412664 |
Kelly K Arthur1, Brent S Kendrick1, John P Gabrielson2.
Abstract
The levels and types of aggregates present in protein biopharmaceuticals must be assessed during all stages of product development, manufacturing, and storage of the finished product. Routine monitoring of aggregate levels in biopharmaceuticals is typically achieved by size exclusion chromatography (SEC) due to its high precision, speed, robustness, and simplicity to operate. However, SEC is error prone and requires careful method development to ensure accuracy of reported aggregate levels. Sedimentation velocity analytical ultracentrifugation (SV-AUC) is an orthogonal technique that can be used to measure protein aggregation without many of the potential inaccuracies of SEC. In this chapter, we discuss applications of SV-AUC during biopharmaceutical development and how characteristics of the technique make it better suited for some applications than others. We then discuss the elements of a comprehensive analytical control strategy for SV-AUC. Successful implementation of these analytical control elements ensures that SV-AUC provides continued value over the long time frames necessary to bring biopharmaceuticals to market.Keywords: Analytical ultracentrifugation; Biopharmaceuticals; Protein aggregation; Sedimentation velocity; Therapeutic proteins
Mesh:
Substances:
Year: 2015 PMID: 26412664 DOI: 10.1016/bs.mie.2015.06.011
Source DB: PubMed Journal: Methods Enzymol ISSN: 0076-6879 Impact factor: 1.600